Showing 7271-7280 of 8649 results for "".
- Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/frontera-therapeutics-doses-first-patient-in-a-trial-of-ft-002-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa/2481415/Frontera Therapeutics announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002, which is being studied for the treatment of X-linked retinitis pigmentosa (XLRP) and is Frontera’s third gene therapy product candidate to enter the clinic.
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Researchers Identify Potential Cause of Keratoconushttps://modernod.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/Researchers at the University of North Texas Health Science Center are the first to characterize extracellular vesicles (EVs) in the tears of patients with keratoconus, according to an National Eye Institute news release. Dimitrios Karamichos, PhD, executive director of the North
- New Phase 3 Data Show Genentech’s Vabysmo Improved Vision and Reduced Retinal Fluid in People with RVOhttps://modernod.com/news/new-phase-3-data-show-genentechs-vabysmo-improved-vision-and-reduced-retinal-fluid-in-people-with-rvo/2481401/Genentech announced positive new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. The studies showed that treatment with Vabysmo resulted in
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Endogena Therapeutics Receives FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-receives-fda-fast-track-designation-for-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481387/The FDA has granted Fast Track designation to Endogena Therapeutics' EA-2353 for the treatment of retinitis pigmentosa (RP). EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into
- SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-unveils-6-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481385/SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased d
- Nidek and Hoya Vision Care Enter Global Partnershiphttps://modernod.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/Nidek has announced a partnership with Hoya Vision Care that would allow Hoya's customers access to Nidek's optical products, services and instruments through both local distributors. Financial terms of the deal were not disclosed. The aim of the partnership
- Roche Names Teresa Graham Head of its Pharma Businesshttps://modernod.com/news/roche-names-teresa-graham-head-of-its-pharma-business/2481379/Teresa Graham, former Genentech executive and current Head of Global Product Strategy for Roche Pharmaceuticals, has been appointed CEO of Roche Pharmaceuticals, based in Basel, Switzerland, effective March 2023. She will also become a member of the Corporate Executive Committee.</